Assessment of the Impact of Reactive Oxygen Species from Repeated Hyperbaric Oxygen Therapy Sessions on DNA Damage in Patients Undergoing Radiotherapy for Cancer

What this Trial Is About

Researchers are studying the effects of Hyperbaric Oxygen Therapy (HBOT) in patients undergoing radiotherapy for cancer or other neoplastic diseases. HBOT involves breathing oxygen at higher than normal pressures, which increases oxygen levels in tissues and promotes wound healing. However, this increased oxygen can produce reactive oxygen species (ROS) that may cause DNA damage and raise long-term cancer risks. The study aims to understand how repeated HBOT sessions impact DNA damage, especially in patients with impaired DNA repair due to cancer or related conditions. Participants will undergo HBOT sessions as part of their treatment for radiation-related complications or other indications. The study involves blood tests taken before and after the first HBOT session and immediately after the last session to measure DNA damage and ROS production. Researchers will track these changes throughout the course of treatment to explore correlations between HBOT, DNA damage, and wound healing after radiotherapy. During the study, participants will provide blood samples at key time points to assess DNA damage and ROS levels. The main outcome is the correlation between HBOT sessions and DNA damage at baseline, after the first session, and after the last session. Additional measures include monitoring ROS formation and examining links between DNA damage and healing of radiation-induced wounds. The study is conducted under medical supervision, ensuring participant safety and thorough evaluation over the treatment period.

Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperbaric Oxygen Therapy in Patients Undergoing Radiotherapy for Neoplasia, on the Occurrence of DNA Damage